Videos

By Sharon Gentry, RN, MSN, AOCN, CBCN, HON-ONN-CG

SABCS 2020 – Wrap-Up

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer. Read More ›

Videos Wrap-Up

Cancer and the COVID-19 Pandemic

By Sharon Gentry, RN, MSN, AOCN, CBCN, HON-ONN-CG

SABCS 2020 – Wrap-Up

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, suggests ways for patients with cancer to remain safe during the COVID-19 pandemic. Read More ›

Videos

What is Minimal Residual Disease (MRD) Negativity?

By Leslie Lauersdorf, ARNP

ASH 2019 – Multiple Myeloma

Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients. Read More ›

Videos

Multiple Myeloma as a Chronic Disease

By Leslie Lauersdorf, ARNP

ASH 2019 – Multiple Myeloma

As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients. Read More ›

Videos

Triplets versus Quads

By Leslie Lauersdorf, ARNP

ASH 2019 – Multiple Myeloma

Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. Read More ›

Videos

CAR T-Cell Data in Multiple Myeloma

By Leslie Lauersdorf, ARNP

ASH 2019 – Multiple Myeloma

Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. Read More ›

Videos

Latest Developments in Multiple Myeloma

By Leslie Lauersdorf, ARNP

ASH 2019 – Multiple Myeloma

Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019. Read More ›

Videos

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

SABCS 2017

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›

Videos

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

SABCS 2017

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›

Videos

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

SABCS 2017

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›

Videos

Page 2 of 4